Literature DB >> 25103499

A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.

Shweta Joshi1, Alok R Singh1, Muamera Zulcic1, Donald L Durden2.   

Abstract

UNLABELLED: Tumor growth, progression, and response to the hypoxic tumor microenvironment involve the action of hypoxia-inducible transcription factors, HIF1 and HIF2. HIF is a heterodimeric transcription factor containing an inducible HIFα subunit and a constitutively expressed HIFβ subunit. The signaling pathways operational in macrophages regulating hypoxia-induced HIFα stabilization remain the subject of intense investigation. Here, it was discovered that the PTEN/PI3K/AKT signaling axis controls hypoxia-induced HIF1α (HIF1A) and HIF2α (EPAS1) stability in macrophages. Using genetic mouse models and pan-PI3K as well as isoform-specific inhibitors, inhibition of the PI3K/AKT pathway blocked the accumulation of HIFα protein and its primary transcriptional target VEGF in response to hypoxia. Moreover, blocking the PI3K/AKT signaling axis promoted the hypoxic degradation of HIFα via the 26S proteasome. Mechanistically, a macrophage-dominant PI3K isoform (p110γ) directed tumor growth, angiogenesis, metastasis, and the HIFα/VEGF axis. Moreover, a pan-PI3K inhibitor (SF1126) blocked tumor-induced angiogenesis and inhibited VEGF and other proangiogenic factors secreted by macrophages. These data define a novel molecular mechanism by which PTEN/PI3K/AKT regulates the proteasome-dependent stability of HIFα under hypoxic conditions, a signaling pathway in macrophages that controls tumor-induced angiogenesis and metastasis. IMPLICATIONS: This study indicates that PI3K inhibitors are excellent candidates for the treatment of cancers where macrophages promote tumor progression. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25103499     DOI: 10.1158/1541-7786.MCR-13-0682

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  56 in total

1.  Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α.

Authors:  Shanshan Lin; Bo Zhu; Guozhi Huang; Qing Zeng; Chuhuai Wang
Journal:  Hum Cell       Date:  2018-11-30       Impact factor: 4.174

2.  Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors.

Authors:  Xueqiong Zhang; Limei Shen; Qi Liu; Lin Hou; Leaf Huang
Journal:  J Control Release       Date:  2019-07-29       Impact factor: 9.776

3.  Tyrosines-740/751 of PDGFRβ contribute to the activation of Akt/Hif1α/TGFβ nexus to drive high glucose-induced glomerular mesangial cell hypertrophy.

Authors:  Falguni Das; Nandini Ghosh-Choudhury; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Cell Signal       Date:  2017-09-23       Impact factor: 4.315

Review 4.  Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis.

Authors:  Massimiliano Mazzone; Gabriele Bergers
Journal:  Annu Rev Physiol       Date:  2019-02-10       Impact factor: 19.318

5.  Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.

Authors:  Forest H Andrews; Alok R Singh; Shweta Joshi; Cassandra A Smith; Guillermo A Morales; Joseph R Garlich; Donald L Durden; Tatiana G Kutateladze
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

6.  Salidroside Inhibits Inflammation Through PI3K/Akt/HIF Signaling After Focal Cerebral Ischemia in Rats.

Authors:  Yicong Wei; Haimian Hong; Xiaoqin Zhang; Wenfang Lai; Yingzheng Wang; Kedan Chu; John Brown; Guizhu Hong; Lidian Chen
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

7.  Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium.

Authors:  Vinod Nadella; Sandhya Singh; Aklank Jain; Manju Jain; Karen M Vasquez; Ashok Sharma; Pranay Tanwar; Goura Kishore Rath; Hridayesh Prakash
Journal:  Mol Carcinog       Date:  2018-08-10       Impact factor: 4.784

8.  Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

Authors:  Catherine A Evans; Tao Liu; André Lescarbeau; Somarajan J Nair; Louis Grenier; Johan A Pradeilles; Quentin Glenadel; Thomas Tibbitts; Ann M Rowley; Jonathan P DiNitto; Erin E Brophy; Erin L O'Hearn; Janid A Ali; David G Winkler; Stanley I Goldstein; Patrick O'Hearn; Christian M Martin; Jennifer G Hoyt; John R Soglia; Culver Cheung; Melissa M Pink; Jennifer L Proctor; Vito J Palombella; Martin R Tremblay; Alfredo C Castro
Journal:  ACS Med Chem Lett       Date:  2016-07-22       Impact factor: 4.345

9.  MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer.

Authors:  Jie Cui; Biao Duan; Xuyang Zhao; Yan Chen; Shixun Sun; Wenjie Deng; Yujie Zhang; Jun Du; Yongchang Chen; Luo Gu
Journal:  Tumour Biol       Date:  2016-07-27

10.  Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Authors:  Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden
Journal:  Mol Cancer Ther       Date:  2016-08-05       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.